Use of Cell-Penetrating Peptides in Dendritic Cell-Based Vaccination

被引：36

作者：

Lim, Sangho ^{[1
,2
]}

Koo, Ja-Hyun ^{[1
,2
]}

Choi, Je-Min ^{[1
,2
]}

机构：

[1] Hanyang Univ, Dept Life Sci, Coll Nat Sci, 222 Wangsimni Ro, Seoul 04763, South Korea

[2] Hanyang Univ, Res Inst Nat Sci, Seoul 04763, South Korea

来源：

IMMUNE NETWORK | 2016年 / 16卷 / 01期

关键词：

Cell-penetrating peptide; Dendritic cell; Vaccination; Immune modulation; MHC CLASS-I; NF-KAPPA-B; ALLERGIC AIRWAY INFLAMMATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; PROTEIN TRANSDUCTION DOMAIN; T-CELLS; ANTIGEN PRESENTATION; ANTITUMOR IMMUNITY; CROSS-PRESENTATION; FUSION PROTEIN;

D O I：

10.4110/in.2016.16.1.33

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cell-penetrating peptides (CPPs) are short amino acids that have been widely used to deliver macromolecules such as proteins, peptides, DNA, or RNA, to control cellular behavior for therapeutic purposes. CPPs have been used to treat immunological diseases through the delivery of immune modulatory molecules in vivo. Their intracellular delivery efficiency is highly synergistic with the cellular characteristics of the dendritic cells (DCs), which actively uptake foreign antigens. DC-based vaccines are primarily generated by pulsing DCs ex vivo with various immunomodulatory antigens. CPP conjugation to antigens would increase DC uptake as well as antigen processing and presentation on both MHC class II and MHC class I molecules, leading to antigen specific CD4(+) and CD8(+) T cell responses. CPP-antigen based DC vaccination is considered a promising tool for cancer immunotherapy due to the enhanced CTL response. In this review, we discuss the various applications of CPPs in immune modulation and DC vaccination, and highlight the advantages and limitations of the current CPP-based DC vaccination.

引用

页码：33 / 43

页数：11

共 110 条

[1] Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination [J].

Aarntzen, Erik H. J. G. ;

Srinivas, Mangala ;

Schreibelt, Gerty ;

Heerschap, Arend ;

Punt, Cornelius J. A. ;

Figdor, Carl G. ;

Oyen, Wim J. ;

de Vries, I. Jolanda M. .

ONCOIMMUNOLOGY, 2013, 2 (07)

[2] Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3′-fluoro-3′-deoxy-thymidine ([18F]FLT) PET imaging [J].

Aarntzen, Erik H. J. G. ;

Srinivas, Mangala ;

De Wilt, Johannes H. W. ;

Jacobs, Joannes F. M. ;

Lesterhuis, W. Joost ;

Windhorst, Albert D. ;

Troost, Esther G. ;

Bonenkamp, Johannes J. ;

van Rossum, Michelle M. ;

Blokx, Willeke A. M. ;

Mus, Roel D. ;

Boerman, Otto C. ;

Punt, Cornelis J. A. ;

Figdor, Carl G. ;

Oyen, Wim J. G. ;

de Vries, I. Jolanda M. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (45) :18396-18399

[3] Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo [J].

Andaloussi, Samir E. L. ;

Lehto, Taavi ;

Maeger, Imre ;

Rosenthal-Aizman, Katri ;

Oprea, Iulian I. ;

Simonson, Oscar E. ;

Sork, Helena ;

Ezzat, Kariem ;

Copolovici, Dana M. ;

Kurrikoff, Kaido ;

Viola, Joana R. ;

Zaghloul, Eman M. ;

Sillard, Rannar ;

Johansson, Henrik J. ;

Hassane, Fatouma Said ;

Guterstam, Peter ;

Suhorutsenko, Julia ;

Moreno, Pedro M. D. ;

Oskolkov, Nikita ;

Haelldin, Jonas ;

Tedebark, Ulf ;

Metspalu, Andres ;

Lebleu, Bernard ;

Lehtioe, Janne ;

Smith, C. I. Edvard ;

Langel, Uelo .

NUCLEIC ACIDS RESEARCH, 2011, 39 (09) :3972-3987

[4] Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A [J].

Aramburu, J ;

Yaffe, MB ;

López-Rodríguez, C ;

Cantley, LC ;

Hogan, PG ;

Rao, A .

SCIENCE, 1999, 285 (5436) :2129-2133

[5] Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting bcr-abl fusion gene in Chronic Myeloid Leukemia cells [J].

Arthanari, Yamini ;

Pluen, Alain ;

Rajendran, Ramkumar ;

Aojula, Harmesh ;

Demonacos, Constantinos .

JOURNAL OF CONTROLLED RELEASE, 2010, 145 (03) :272-280

[6]

BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141

[7] Dendritic cells and the control of immunity [J].

Banchereau, J ;

Steinman, RM .

NATURE, 1998, 392 (6673) :245-252

[8] Cell-penetrating peptides: 20 years later, where do we stand? [J].

Bechara, Cherine ;

Sagan, Sandrine .

FEBS LETTERS, 2013, 587 (12) :1693-1702

[9] Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer [J].

Bolhassani, Azam .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2011, 1816 (02) :232-246

[10] Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance [J].

Bonifaz, L ;

Bonnyay, D ;

Mahnke, K ;

Rivera, M ;

Nussenzweig, MC ;

Steinman, RM .

JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (12) :1627-1638

← 1 2 3 4 5 6 7 8 9 10 →